<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178304</url>
  </required_header>
  <id_info>
    <org_study_id>0201167</org_study_id>
    <nct_id>NCT04178304</nct_id>
  </id_info>
  <brief_title>Effect of Prolotherapy in Knee Osteoarthritis.</brief_title>
  <official_title>Effect of Prolotherapy in Knee Osteoarthritis: Clinical and Ultrasonographic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with primary knee osteoarthritis will be included in the study, plain X-ray for the
      affected knee, followed by musculoskeletal ultrasound assessment will be done. The
      intervention: intra-articular injection and extra-articular injections of 25% dextrose.
      Follow up will be done at 24 weeks after the last injection both clinically and
      ultrasonographically .

      Aim: Determine whether prolotherapy improves pain. stiffness and function of symptomatic knee
      osteoarthritis and determine ultrasonographic changes before and after prolotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty knees with primary knee osteoarthritis will be included in the study, clinical
      assessment will be done, then plain X-ray for the affected knee (s), followed by
      musculoskeletal ultrasound assessment will be done.

      The intervention:

        1. a single intra-articular injection of 6 mL of 25% dextrose through infero-medial or
           infero-lateral approach will be done.

        2. extra-articular injections will be done at major tender tendons and ligaments through 15
           skin punctures using peppering technique and placing a possible total of 22.5 mL of 25%
           dextrose. Injections will be done at 1, 5, 9, and 13 weeks intervals.

      Follow up will be done at 24 weeks after the last injection both clinically and
      ultrasonographically .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Fifty knees with primary knee osteoarthritis will be included in the study, plain X-ray for the affected knee, followed by musculoskeletal ultrasound assessment will be done. The intervention: 1. a single intra-articular injection of 6 mL of 25% dextrose through infero-medial or infero-lateral approach will be done. 2. extra-articular injections will be done at major tender tendons and ligaments through 15 skin punctures using peppering technique and placing a possible total of 22.5 mL of 25% dextrose. Injections will be done at 1, 5, 9, and 13 weeks intervals. Follow up will be done at 24 weeks after the last injection both clinically and ultrasounographicly.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>the Assessor doing the musculoskeletal ultrasound will be masked to the radiographic grading of knee osteoarthritis, the clinical condition and the improvement following prolotgerapy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Physical function</measure>
    <time_frame>24 weeks after last injection</time_frame>
    <description>whether prolotherapy improves physical function by Western Ontario and McMaster University (WOMAC) index in patients with primary knee osteoarthritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cartilage thickness</measure>
    <time_frame>24 weeks after last injection</time_frame>
    <description>whether an increase in cartilage thickness could be detected by the musculoskeletal ultrasound following prolotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>24 weeks after last injection</time_frame>
    <description>safety and tolerability will be assessed using patient satisfaction Likeret 5 point scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>G1 patients receive prolotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra and extra articular dextrose 25%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolotherapy with 25% Dextrose</intervention_name>
    <description>Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose</description>
    <arm_group_label>G1 patients receive prolotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate and moderate to severe primary Knee osteoarthritis (KL grade II and III)

          -  consent obtained

        Exclusion Criteria:

          -  Severe Knee osteoarthritis (KL grade IV)

          -  Causes of 2ry osteoarthritis: other rheumatological, metabolic and inflammatory joint
             diseases.

          -  received oral or systemic steroids 1 month prior to the procedure

          -  received intra-articular steroids or hyaluronic acid 1 month prior to the procedure

          -  BMI &gt;45Kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yousra Hisham H Abdel Fattah</last_name>
    <phone>+20127320303</phone>
    <email>yousrahisham@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandria University, Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>00123</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousra H Abdel Fattah</last_name>
      <phone>127320303</phone>
      <email>yousrahisham@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Safaa I Mostafa, masters</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diaa F Mohasseb, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hesham T Kotb, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hoda M Abdelnaby, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>January 4, 2020</last_update_submitted>
  <last_update_submitted_qc>January 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Yousra Hisham Abdel Fattah</investigator_full_name>
    <investigator_title>Lecturer of Physical Medicine, Rheumatology and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>primary knee osteoarthritis,</keyword>
  <keyword>prolotherapy,</keyword>
  <keyword>musculoskeletal ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

